Covered recipient · General Payments record
HASHEM B EL-SERAG
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
General Payments · PY2018–2024
$70,066.86
- Reported across 66 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $8,137.50 | 2 |
| Honoraria | $3,115.00 | 2 |
| Food and Beverage | $552.63 | 7 |
| Travel and Lodging | $306.31 | 3 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $8,592.48 | 6 |
| Madrigal Pharmaceuticals | $2,250.52 | 2 |
| Phathom Pharmaceuticals, Inc. | $1,069.85 | 2 |
| Genentech USA, Inc. | $119.25 | 1 |
| ABBVIE INC. | $54.42 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.92 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.81 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103683201 | CMS |
| ABBVIE INC. | $29.61 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103683203 | CMS |
| Genentech USA, Inc. | $119.25 | 09/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133019197 | CMS |
| Madrigal Pharmaceuticals | $135.52 | 11/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144165133 | CMS |
| Madrigal Pharmaceuticals | $2,115.00 | 12/05/2024 | Honoraria | Undisputed | 01/23/2026 | 1144165135 | CMS |
| Novo Nordisk Inc | $775.00 | 09/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1097116994 | CMS |
| Novo Nordisk Inc | $23.40 | 09/19/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096570604 | CMS |
| Novo Nordisk Inc | $60.62 | 09/19/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096620486 | CMS |
| Novo Nordisk Inc | $222.29 | 09/19/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1096633627 | CMS |
| Novo Nordisk Inc | $7,362.50 | 09/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1096921458 | CMS |
| Novo Nordisk Inc | $148.67 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097802063 | CMS |
| Phathom Pharmaceuticals, Inc. | $69.85 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151058227 | CMS |
| Phathom Pharmaceuticals, Inc. | $1,000.00 | 05/22/2024 | Honoraria | Undisputed | 01/23/2026 | 1151058229 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $24.92 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137538779 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.